Shen Yin

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar et al. · The Lancet Oncology · 2022 · 390 citations

Lymphoid Neoplasia, Bispecific Antibody, Medicine +7

Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines.

Jayne C. Boyer, Asad Umar, John I. Risinger et al. · PubMed · 1995 · 301 citations

Cancer Pathology, Genetics, Pathology +16

Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines

Stephen J. Schuster, Nancy L. Bartlett, Sarit Assouline et al. · Blood · 2019 · 179 citations

Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory B-cell lymphomas

Stephen J. Schuster, Ling‐Yuh Huw, Christopher R. Bolen et al. · Blood · 2023 · 62 citations · Full text

Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

Lihua E. Budde, Laurie H. Sehn, Sarit Assouline et al. · Blood · 2018 · 59 citations